Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: sanderink gj. Clin Cancer Res. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758. Clin Cancer Res. 2005. PMID: 15746053 Free article. Clinical Trial.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: sanderink gj. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Schoemaker NE, et al. Among authors: sanderink gj. Cancer Chemother Pharmacol. 2005 Mar;55(3):263-70. doi: 10.1007/s00280-004-0874-2. Epub 2004 Nov 16. Cancer Chemother Pharmacol. 2005. PMID: 15592838 Clinical Trial.
27 results